Last reviewed · How we verify
Treatment sequence B
At a glance
| Generic name | Treatment sequence B |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults (PHASE1)
- A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood (PHASE1)
- Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease (PHASE2)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- Human Bioequivalence Study of Liposomal Amphotericin B for Injection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment sequence B CI brief — competitive landscape report
- Treatment sequence B updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI